Implementations of a topical homeopathic formulation may include an active portion including a plurality of active ingredients and a base including a plurality of inactive ingredients. The plurality of active ingredients may include one of tinctures and homeopathic preparations of Apis mellifica, Arnica montana, Atropa belladonna, Bellis perennis, Bryonia alba, Cactus grandifloras, Caulophyllum thalictroides, Cimicifuga racemose, Citrullus colocynthis, Cyclamen europaeum, Gelsemium Sempervirens, Gnaphalium polycephalum, Jonesia asoca, Juniperus Sabina, Kali carbonicum, Lilium tigrinum, Rhamnus californica, Tilia europaea, Viburnum opulus, and any combination thereof.

Implementations of a topical homeopathic formulation may include an active portion including a plurality of active ingredients and a base including a plurality of inactive ingredients. The plurality of active ingredients may include one of tinctures and homeopathic preparations of Apis mellifica, Arnica montana, Atropa belladonna, Bellis perennis, Bryonia alba, Cactus grandifloras, Caulophyllum thalictroides, Cimicifuga racemose, Citrullus colocynthis, Cyclamen europaeum, Gelsemium Sempervirens, Gnaphalium polycephalum, Jonesia asoca, Juniperus Sabina, Kali carbonicum, Lilium tigrinum, Rhamnus californica, Tilia europaea, Viburnum opulus, and any combination thereof.

A first embodiment of a composition for treating vitiligo includes Cassia tora powder, Saussurea lappa root powder, Punica granatum L. (pomegranate) peels powder, and Psoralea corylifolia black seed powder. A second embodiment of a composition for treating vitiligo can include Cassia tora powder, Saussurea lappa root powder, Punica granatum L. (pomegranate) peels powder, Berberries (or Berberis) vulgaris root powder, red clay (with trace copper), and Ptychotis verticillata root powder. Topical administration of the first composition followed by UV radiation exposure can facilitate inducing melanogenesis as well as generating ROS. Topical administration of the second composition following the UV radiation exposure can scavenge the ROS generated by the first composition.

A first embodiment of a composition for treating vitiligo includes Cassia tora powder, Saussurea lappa root powder, Punica granatum L. (pomegranate) peels powder, and Psoralea corylifolia black seed powder. A second embodiment of a composition for treating vitiligo can include Cassia tora powder, Saussurea lappa root powder, Punica granatum L. (pomegranate) peels powder, Berberries (or Berberis) vulgaris root powder, red clay (with trace copper), and Ptychotis verticillata root powder. Topical administration of the first composition followed by UV radiation exposure can facilitate inducing melanogenesis as well as generating ROS. Topical administration of the second composition following the UV radiation exposure can scavenge the ROS generated by the first composition.

A first embodiment of a composition for treating vitiligo includes Cassia tora powder, Saussurea lappa root powder, Punica granatum L. (pomegranate) peels powder, and Psoralea corylifolia black seed powder. A second embodiment of a composition for treating vitiligo can include Cassia tora powder, Saussurea lappa root powder, Punica granatum L. (pomegranate) peels powder, Berberries (or Berberis) vulgaris root powder, red clay (with trace copper), and Ptychotis verticillata root powder. Topical administration of the first composition followed by UV radiation exposure can facilitate inducing melanogenesis as well as generating ROS. Topical administration of the second composition following the UV radiation exposure can scavenge the ROS generated by the first composition.

The present invention relates to a new composition for use in the treatment of cough comprising, as sole active principles, Plantago lanceolata extract, honey, cane sugar, Thymus sp. extract and optionally Sambucus nigra juice.

Compositions and methods for nutraceutical compositions and methods for dietary alleviation of polycystic ovary syndrome (PCOS). Compositions may include at least one anti-hyperandrogenism ingredient. Compositions may include at least one insulin-sensitivity modulating ingredient. The anti-hyperandrogenism ingredient may include inositol. The anti-hyperandrogenism ingredient may include monacolin K (red yeast). The insulin-sensitivity modulating ingredient may include inositol. The insulin-sensitivity modulating ingredient may include curcumin. The methods may include oral administration of the compositions. The methods may include physician monitoring of symptoms during use of the compositions. Case studies demonstrate positive benefits of application of the compositions and methods in alleviation of PCOS. Demonstrated benefits include conception after lengthy infertility prior to application of the compositions and methods. The methods may include formulation into a single over-the-counter composition for use in a supplement that a patient may self-administer in the treatment of PCOS, improvement of menstrual cyclicity and reversal of infertility.

Compositions and methods for nutraceutical compositions and methods for dietary alleviation of polycystic ovary syndrome (PCOS). Compositions may include at least one anti-hyperandrogenism ingredient. Compositions may include at least one insulin-sensitivity modulating ingredient. The anti-hyperandrogenism ingredient may include inositol. The anti-hyperandrogenism ingredient may include monacolin K (red yeast). The insulin-sensitivity modulating ingredient may include inositol. The insulin-sensitivity modulating ingredient may include curcumin. The methods may include oral administration of the compositions. The methods may include physician monitoring of symptoms during use of the compositions. Case studies demonstrate positive benefits of application of the compositions and methods in alleviation of PCOS. Demonstrated benefits include conception after lengthy infertility prior to application of the compositions and methods. The methods may include formulation into a single over-the-counter composition for use in a supplement that a patient may self-administer in the treatment of PCOS, improvement of menstrual cyclicity and reversal of infertility.

The present invention relates to a process for extraction and freeze-drying of a Berberis extract. More particularly, the invention provides an optimized process for freeze-drying/lyophilization to increase the solubility of the extract into the surfactants for enhanced incorporation into a nano-carrier system. Furthermore, the present invention also relates to a lipid nano-formulation of freeze-dried Berberis extract and process for preparing the same by high-pressure homogenization. The invention also relates to the lipid nano-formulation of freeze-dried Berberis extract for efficient drug delivery, for dermatological and cosmeceutical purposes, for treating diabetes and diabetes associated complications, as a wound healer, as an antimicrobial, as an anti-infective, as an anti-inflammatory agent and as an antioxidant.

The present invention relates to a process for extraction and freeze-drying of a Berberis extract. More particularly, the invention provides an optimized process for freeze-drying/lyophilization to increase the solubility of the extract into the surfactants for enhanced incorporation into a nano-carrier system. Furthermore, the present invention also relates to a lipid nano-formulation of freeze-dried Berberis extract and process for preparing the same by high-pressure homogenization. The invention also relates to the lipid nano-formulation of freeze-dried Berberis extract for efficient drug delivery, for dermatological and cosmeceutical purposes, for treating diabetes and diabetes associated complications, as a wound healer, as an antimicrobial, as an anti-infective, as an anti-inflammatory agent and as an antioxidant.